INO
The headline: still alive, still waiting
Inovio’s first-quarter update had the vibes of a biotech living room makeover: not flashy, but designed to make the place look ready for company. The big item is INO-3107, which is now under FDA review through the accelerated approval program, with a PDUFA date of October 30th, 2026.
Why investors are paying attention
That date matters because it’s the difference between “promising science” and “okay, does this turn into actual revenue?” Inovio says commercial readiness work is already underway for a potential launch of INO-3107 in adults with recurrent respiratory papillomatosis, so this isn’t just a science fair project anymore.
- The company’s cash, cash equivalents, and short-term investments are expected to fund operations into first quarter 2027.
- That means Inovio should, in theory, make it past the PDUFA deadline without immediately sprinting back to the capital markets.
- For a small-cap biotech, that’s a rare little luxury.
A second shot on goal
Inovio also announced a clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 with cadonilimab in a Dana-Farber Cancer Institute-sponsored glioblastoma trial. Translation: another attempt to turn platform potential into something investors can actually model without squinting.
Big picture: this was a classic biotech update—no moon landing, but enough regulatory momentum and cash visibility to keep the story interesting.